Avacta Group Plc

  • Market Cap: Small Cap
  • Industry: Miscellaneous
  • ISIN: GB00BYYW9G87
GBP
0.68
0.35 (104.55%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Miscellaneous

stock-summary
Market cap

GBP 291 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

6.77

stock-summary
Return on Equity

-3,485.40%

stock-summary
Price to Book

290.67

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
73.08%
0%
73.08%
6 Months
54.29%
0%
54.29%
1 Year
66.67%
0%
66.67%
2 Years
-38.07%
0%
-38.07%
3 Years
-47.17%
0%
-47.17%
4 Years
-69.17%
0%
-69.17%
5 Years
-54.07%
0%
-54.07%

Avacta Group Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
37.90%
EBIT Growth (5y)
-190.89%
EBIT to Interest (avg)
-13.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.92
Sales to Capital Employed (avg)
0.13
Tax Ratio
7.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
309.88
EV to EBIT
-11.14
EV to EBITDA
-12.31
EV to Capital Employed
45.79
EV to Sales
27.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-411.12%
ROE (Latest)
-3715.00%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Avacta Group Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -96.55% vs -70.10% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -0.68% vs 21.08% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "2.90",
          "chgp": "-96.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.20",
          "val2": "-20.70",
          "chgp": "-45.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "10.10",
          "val2": "14.90",
          "chgp": "-32.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "13.00",
          "val2": "6.00",
          "chgp": "116.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-29.40",
          "val2": "-29.20",
          "chgp": "-0.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-280,238.90%",
          "val2": "-7,718.30%",
          "chgp": "-27,252.06%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
0.10
2.90
-96.55%
Operating Profit (PBDIT) excl Other Income
-30.20
-20.70
-45.89%
Interest
10.10
14.90
-32.21%
Exceptional Items
13.00
6.00
116.67%
Consolidate Net Profit
-29.40
-29.20
-0.68%
Operating Profit Margin (Excl OI)
-280,238.90%
-7,718.30%
-27,252.06%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -96.55% vs -70.10% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -0.68% vs 21.08% in Dec 2023

stock-summaryCompany CV
About Avacta Group Plc stock-summary
stock-summary
Avacta Group Plc
Miscellaneous
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Company Coordinates stock-summary
Company Details
Unit 20, Ash Way , WETHERBY None : LS23 7FA
Registrar Details